Your session is about to expire
← Back to Search
Isatuximab for Smoldering Multiple Myeloma
Study Summary
This trial looks at how well a monoclonal antibody called isatuximab works in treating patients with smoldering plasma cell myeloma that is high risk.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 307 Patients • NCT02990338Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not undergone radiotherapy.Your blood calcium levels are too high.I do not have any uncontrolled illnesses like high blood pressure or heart problems.My kidney function is reduced with specific test results.I have not had major surgery in the last month.I am not allergic or unable to take any medication required before therapy.I do not have an uncontrolled lung condition.I have one or more bone lesions detectable by scans.I am at high risk of my condition progressing to multiple myeloma according to PETHEMA criteria.I am 18 years old or older.I am able to get out of my bed or chair and move around.I agree to use birth control to prevent pregnancy during the study.I have SMM with specific protein levels in my blood or urine, or a certain percentage of plasma cells in my bone marrow.You are allergic to certain ingredients in infused protein products.Your bone marrow contains a high percentage of abnormal plasma cells.I have not used chemotherapy or CD38 drugs for smoldering multiple myeloma.I agree not to donate sperm during and for 5 months after the study.Your test shows that the ratio of certain proteins in your blood is very high.If you are a woman who could become pregnant, you need to have a negative pregnancy test before starting the treatment and at the end of the treatment.I do not have an active hepatitis B or C infection.My liver tests are within normal limits.You have more than one specific spot on your MRI, and each spot is at least 5 millimeters in size.Your hemoglobin level is lower than 10 g/dL or higher than 2 g/dL than the normal range.I am taking medication for bone health.Your white blood cell count, red blood cell count, and platelet count are within a certain range.I have been diagnosed with plasma cell leukemia.I am not currently receiving any other cancer treatments.I am HIV positive.Your kidneys work well enough to clear at least 40 milliliters of creatinine from your body every minute.My tests show signs of myeloma or cancerous cell growth.I am not on corticosteroids, except for stable doses for respiratory diseases or hormone disorders.
- Group 1: Treatment (isatuximab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do you know of any other research studies that have used Isatuximab?
"Isatuximab was first studied in 2010 at site 604001. 574 completed trials later, there are presently 46 active clinical studies being conducted - a significant number of which taking place in Houston, Texas."
Is this a closed or open clinical trial?
"The latest information available on clinicaltrials.gov suggests that this trial is still recruiting patients. The listing was created on 2/8/2017 and updated for the 9/28/2022."
What other similar trials have been conducted in the past?
"Since first being studied in 2010, Isatuximab has undergone 46 clinical trials across 358 cities and 39 countries."
What is the official stance of the FDA on Isatuximab?
"Isatuximab's safety is tentatively rated as a 2. This score comes from it being a Phase 2 trial, where there some data supporting safety but not efficacy."
How many people are allowed to join this research project?
"That is correct, the online clinicaltrials.gov registry currently lists this study as open and recruiting. The trial was first advertised on February 8th, 2017 and was most recently updated on September 28th, 2022. They are looking to enroll 61 individuals at 2 sites total."
Share this study with friends
Copy Link
Messenger